Guggenheim Starts Coverage of Tyra Biosciences with Buy Rating
Dow Jones Newswires reports that Guggenheim has begun coverage of Tyra Biosciences with a Buy rating and a $55.00 per share price target.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that Guggenheim has taken over coverage of Tyra Biosciences and rated the company's shares Buy. The brokerage set a price target of $55.00 per share.
The information was published on November 20, 2026, at 13:46 GMT.
why it matters
This is a single analyst rating for one biotech company, so its impact on broader markets is limited. Such notes mainly matter to investors following Tyra Biosciences shares and the biotech sector.
tags
instruments
sources
- Tyra Biosciences Coverage Assumed by Guggenheim at Buy — Dow Jones Newswires, 20 November 2026 at 13:46 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗